Pfizer secured FDA approval for the generic formulation of its blockbuster antibiotic Zithromax, a move that is expected to drive immediate market competition in the azithromycin dihydrate sector. As the expiration of the key brand patent accelerates generic erosion, this approval signals a potential revenue downturn for the product line while increasing accessibility for patients.